GB
Therapeutic Areas
Aquestive Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Anaphylm™ (AQST-109) | Severe allergic reactions, including anaphylaxis | Phase 3 |
| Libervant® (diazepam buccal film) | Acute repetitive seizure clusters in epilepsy | Approved |
| AQST-305 | Potential dermatology conditions (e.g., atopic dermatitis) | Preclinical |
Leadership Team at Aquestive Therapeutics
DB
Daniel Barber
President and Chief Executive Officer
ET
Ernie Toth
Chief Financial Officer
MW
Matthew W. Davis, M.D.
Chief Development Officer
MG
Matthew Greenhawt, M.D.
Chief Medical Officer
CJ
Cassie Jung
Chief Operating Officer
SK
Sherry Korczynski
Chief Commercial Officer
LJ
Lori J. Braender
Chief Legal Officer, Chief Compliance Officer and Secretary
PB
Peter Boyd
Chief People Officer
MT
Melina T. Cioffi, Pharm.D.
Senior Vice President, Regulatory Affairs
JC
John Cochran
Director